Georgios Kalogeropoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Georgios Kalogeropoulos has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Andreas Kartsonakis
Internal Medicine, "Agios Andreas" General Hospital, Patras, Achaia, 26335, Greece
1 shared publication- Antonios Patrinos
General and Oncologic Hospital of Kifissia 'Agioi Anargyroi', Athens, Greece
1 shared publication Dimitra Dimitropoulou
Internal Medicine, "Agios Andreas" General Hospital, Patras, Achaia, 26335, Greece
1 shared publication- Dimitrios Komninos
Department of Respiratory Medicine, University Hospital of Patras, 26500 Patras, Greece
1 shared publication Dimitris Serpanos
Internal Medicine, "Agios Andreas" General Hospital, Patras, Achaia, 26335, Greece
1 shared publicationKaterina Dimouli
Internal Medicine, "Agios Andreas" General Hospital, Patras, Achaia, 26335, Greece
1 shared publication
Latest Publications
- Open Access
- 6 July 2021
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 540
Case Report: An immunocompromised, vaccine breakthrough COVID-19 patient with pneumonia
Background: The novel SARS-CoV-2 pandemic has inflicted a major blow on public health worldwide accounting for millions of deaths and subsequent socio-economic consequences. The main challenge for scientists and researchers has been to restrain transmission of the virus and prevent severe respiratory disease. Novel promising vaccines aim to fulfil these expectations, although new variants of the coronavirus have emerged. The present manuscript aims to add to the knowledge, through a case of an immunodeficient patient, who developed remarkably favorable recovery from SARS-CoV-2 pneumonia after having been fully vaccinated against the novel coronavirus. Case presentation: An 82-year-old Caucasian male with a history of metastatic pancreatic cancer was admitted with signs and symptoms of pneumonia. Workup revealed a positive SARS-CoV-2 real time – polymerase chain reaction (RT-PCR) and further investigation identified a B.1.1.7 variant. The imaging essays showed extensive lung disease. Interestingly, the patient had already received the second dose of the BNT162b2 (Pfizer) vaccine against the new coronavirus 16 days prior. After having been treated with appropriate antiviral and antibiotical agents the patient showed significantly favorable recovery and no need for high oxygen flows and no complications presented. The patient was discharged after six days of hospitalization in good condition, with no need for supplementary oxygen at home. Conclusions: Despite breakthrough cases, vaccination against COVID-19 is crucial for restraining the novel coronavirus. Further studies should be carried out in order to determine the optimal strategies for large-scale vaccination while minimizing the risk of further and faster evolution of the virus.
- 6 July 2021
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 540
Open AccessCase Report: An immunocompromised, vaccine breakthrough COVID-19 patient with pneumonia
Background: The novel SARS-CoV-2 pandemic has inflicted a major blow on public health worldwide accounting for millions of deaths and subsequent socio-economic consequences. The main challenge for scientists and researchers has been to restrain transmission of the virus and prevent severe respiratory disease. Novel promising vaccines aim to fulfil these expectations, although new variants of the coronavirus have emerged. The present manuscript aims to add to the knowledge, through a case of an immunodeficient patient, who developed remarkably favorable recovery from SARS-CoV-2 pneumonia after having been fully vaccinated against the novel coronavirus. Case presentation: An 82-year-old Caucasian male with a history of metastatic pancreatic cancer was admitted with signs and symptoms of pneumonia. Workup revealed a positive SARS-CoV-2 real time – polymerase chain reaction (RT-PCR) and further investigation identified a B.1.1.7 variant. The imaging essays showed extensive lung disease. Interestingly, the patient had already received the second dose of the BNT162b2 (Pfizer) vaccine against the new coronavirus 16 days prior. After having been treated with appropriate antiviral and antibiotical agents the patient showed significantly favorable recovery and no need for high oxygen flows and no complications presented. The patient was discharged after six days of hospitalization in good condition, with no need for supplementary oxygen at home. Conclusions: Despite breakthrough cases, vaccination against COVID-19 is crucial for restraining the novel coronavirus. Further studies should be carried out in order to determine the optimal strategies for large-scale vaccination while minimizing the risk of further and faster evolution of the virus.